成人肾肉瘤的综合基因组分析揭示疾病生物学与靶向治疗机会
该研究对13例成人局部晚期或转移性肾肉瘤进行综合基因组分析,发现每例平均4.2个基因组改变,其中2.2个为临床相关改变;69%的病例携带至少一个临床相关改变,31%存在KIT/PDGFRA/KDR基因4q12扩增。所有肿瘤均为微卫星稳定,平均肿瘤突变负荷3.5个突变/Mb,无病例超过10个突变/Mb。
要点
- 肾肉瘤中31%存在4q12扩增涉及KIT/PDGFRA/KDR基因
- 69%的病例携带临床相关基因组改变,可能从靶向治疗获益
- 所有肾肉瘤均为微卫星稳定且肿瘤突变负荷低,不太可能对检查点抑制剂应答
核心结论
- 肾肉瘤具有多样组织学和基因组特征,31%的病例存在4q12扩增包含KIT/PDGFRA/KDR基因。
- 69%的肿瘤携带临床相关基因组改变,可能从靶向治疗中获益,但低肿瘤突变负荷提示不太可能对检查点抑制剂应答。
研究设计与样本
- 对13例成人局部晚期或转移性肾肉瘤(各种组织学类型)的福尔马林固定石蜡包埋组织提取DNA/RNA,使用FoundationOne Heme/Sarcoma检测进行综合基因组分析。
主要发现
- 综合基因组分析共发现55个基因组改变(每肿瘤4.2个),其中29个为临床相关基因组改变(每肿瘤2.2个)。
- 9例(69%)检测到至少一个临床相关基因组改变。
- 4例(31%)发现涉及KIT和PDGFRA基因4q12扩增子的高水平扩增(超过6拷贝),包括2例未分化多形性肉瘤、1例肉瘤样肾细胞癌和1例黏液纤维肉瘤;两例未分化多形性肉瘤还伴有KDR基因扩增。
- 其他临床相关基因组改变见于CDKN2A/B(23%)、NF1(23%)和MET(8%)。
- 所有肾肉瘤均为微卫星稳定,平均肿瘤突变负荷为3.5个突变/Mb,无病例(0%)肿瘤突变负荷超过10个突变/Mb。
关键数值与推荐
- 高水平扩增定义为超过6拷贝。
- 临床相关基因组改变在9例(69%)中检出。
- 4q12扩增(包含KIT/PDGFRA/KDR)在4例(31%)中检出。
- 平均肿瘤突变负荷3.5个突变/Mb,无病例超过10个突变/Mb。
临床怎么用
- 对肾肉瘤进行综合基因组分析可识别携带临床相关基因组改变的患者,或可考虑靶向治疗。
- 低肿瘤突变负荷和微卫星稳定状态提示肾肉瘤患者不太可能从检查点抑制剂治疗中获益。
局限性
- 样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary adult renal sarcomas (RSs) are rare aggressive neoplasms. Clinical outcomes are extremely poor, and optimal treatment remains challenging. OBJECTIVE: To identify genomic alterations (GAs) in patients with RSs. DESIGN, SETTING, AND PARTICIPANTS: Comprehensive genomic profiling (CGP) was conducted on DNA/RNA extracted from formalin-fixed paraffin-embedded tissue using the FoundationOne Heme/Sarcoma assay in 13 adult, locally advanced or metastatic RSs of various histologic types. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All classes of GAs, including base substitutions, small indels, rearrangements, copy number alterations, tumor mutational burden (TMB), and microsatellite instability (MSI), were analyzed. RESULTS AND LIMITATIONS: CGP revealed 55 GAs (4.2 per tumor), 29 of which were clinically relevant genomic alterations (CRGAs; 2.2 per tumor). At least one CRGA was detected in nine (69%) cases. High-level amplifications (more than six copies) involving 4q12 amplicon of the KIT and PDGFRA genes were identified in four (31%) cases (two undifferentiated pleomorphic sarcomas [UPSs], one sarcomatoid renal cell carcinoma, and one myxofibrosarcoma). Both UPSs also had KDR gene amplification in addition to KIT and PDGFRA. Additional CRGAs were found in CDKN2A/B (23%), NF1 (23%), and MET (8%). All RSs were MSI stable, the mean TMB was 3.5 mutations/megabase (Mb), and none (0%) featured TMB >10 mutations/Mb. Limitations include the small sample size. CONCLUSIONS: RSs are characterized by diverse histology and genomic profiles including 31% of cases with 4q12 amplification harboring the KIT/PDGFRA/KDR genes. Of the tumors, 69% carry CRGAs, which could lead to potential benefit from targeted therapies; however, a low TMB also suggests that these cases are unlikely to respond to checkpoint inhibitors. PATIENT SUMMARY: This study provides insights into molecular biology of renal sarcoma, a rare aggressive subtype of kidney tumors. We demonstrated that renal sarcomas harbor unique, recurrent, clinically relevant molecular abnormalities that provide new opportunities for targeted therapies.
引用
- Yakirevich E, Madison R, Fridman E, et al. Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies. Eur Urol Oncol. 2019. PMID: 31412008. doi:10.1016/j.euo.2019.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。